Docoh
Loading...

MOR Morphosys

254 filings

Newest first
Filter options loading...
Top filers
Top filing types
Recent filing years
6-K
MOR Morphosys AG
11 Jan 22
Current report (foreign)
10:08am
6-K
MOR Morphosys AG
10 Jan 22
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
12:34pm
6-K
MOR Morphosys AG
7 Jan 22
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
6:39am
6-K
MOR Morphosys AG
13 Dec 21
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
10:14am
6-K
MOR Morphosys AG
13 Dec 21
Current report (foreign)
9:56am
6-K
MOR Morphosys AG
7 Dec 21
Current report (foreign)
6:01am
6-K
MOR Morphosys AG
29 Nov 21
Current report (foreign)
4:09pm
6-K
MOR Morphosys AG
26 Nov 21
Current report (foreign)
8:15am
6-K
MOR Morphosys AG
23 Nov 21
Current report (foreign)
10:32am
6-K
MOR Morphosys AG
12 Nov 21
MorphoSys AG Reports First Nine Months and Third Quarter
8:30am
6-K
MOR Morphosys AG
10 Nov 21
Third Quarter Interim Statement JANUARY – SEPTEMBER
4:05pm
6-K
MOR Morphosys AG
10 Nov 21
MorphoSys Announces Departure of Roland Wandeler
6:14am
6-K
MOR Morphosys AG
5 Nov 21
MorphoSys presents interim results from M-PLACE study with felzartamab during American Society of Nephrology Annual Meeting
7:13am
6-K
MOR Morphosys AG
4 Nov 21
Current report (foreign)
9:50am
6-K
MOR Morphosys AG
2 Nov 21
Current report (foreign)
11:44am
S-8
MOR Morphosys AG
27 Oct 21
Registration of securities for employees
11:32am
UPLOAD
MOR Morphosys AG
25 Oct 21
Letter from SEC
8:00pm
6-K
MOR Morphosys AG
20 Oct 21
Current report (foreign)
4:09pm
6-K
MOR Morphosys AG
12 Oct 21
MorphoSys’ Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer’s Disease
6:20am
CORRESP
MOR Morphosys AG
11 Oct 21
Correspondence with SEC
8:00pm